Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany-Reference-Cited by-同舟云学术

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Published:2023-10-27 Issue:1 Volume:22 Page:921-932
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Kühne Felicitas¹,Achtert Katharina²,Püschner Franziska²,Urbanski-Rini Dominika²,Schiller Juliane²,Mahar Ernestine¹,Friedrich Josephine¹,Atwood Mark³,Sprenger Ralf¹,Vietri Jeffrey⁴,von Eiff Christof¹,Theilacker Christian⁴

Affiliation:

1. Pfizer Pharma GmbH, Berlin, Germany

2. Private Institute for Applied Health Services Research (inav), Berlin, Germany

3. Policy Analysis Inc, Boston, Massachusetts, USA

4. Pfizer Inc, Collegeville, PA, USA

Funder

Pfizer Pharma GmbH

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2023.2262575

Reference79 articles.

1. Pneumokokkenimpfstoffe

2. Ambulant erworbene Pneumonie: Bundesauswertung zum Erfassungsjahr 2019. IQTIG–Institut für Qualitätssicherung und Transparenz im Gesundheitswesen B; 2020.

3. Population-based incidence and mortality of community-acquired pneumonia in Germany

4. Robert Koch Institut. SurvStat@RKI 2.0 Web-basierte Abfrage der Meldedaten gemäß Infektionsschutzgesetz (IfSG) 2021. Rober Koch Institut; 2021.

5. Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nach der COVID-19-Pandemie – welche neuen Impfungen im Erwachsenenalter sind schon oder bald verfügbar?;Die Innere Medizin;2023-12-18